GEP201706766B - Methods and compositions for vaccinating against staphylococcus aureus - Google Patents

Methods and compositions for vaccinating against staphylococcus aureus

Info

Publication number
GEP201706766B
GEP201706766B GEAP201213225A GEAP2012013225A GEP201706766B GE P201706766 B GEP201706766 B GE P201706766B GE AP201213225 A GEAP201213225 A GE AP201213225A GE AP2012013225 A GEAP2012013225 A GE AP2012013225A GE P201706766 B GEP201706766 B GE P201706766B
Authority
GE
Georgia
Prior art keywords
staphylococcus aureus
against staphylococcus
mammal
compositions
methods
Prior art date
Application number
GEAP201213225A
Other languages
English (en)
Inventor
Scott G Filler
Ashraf S Ibrahim
Yue Fu
John P Hennessey Jr
Michael R Yeaman
John E Edwards Jr
Original Assignee
Los Angeles Biomedical Res Center
Novamedica Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Biomedical Res Center, Novamedica Llc filed Critical Los Angeles Biomedical Res Center
Publication of GEP201706766B publication Critical patent/GEP201706766B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GEAP201213225A 2011-07-22 2012-07-20 Methods and compositions for vaccinating against staphylococcus aureus GEP201706766B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161510896P 2011-07-22 2011-07-22

Publications (1)

Publication Number Publication Date
GEP201706766B true GEP201706766B (en) 2017-10-25

Family

ID=47601425

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP201213225A GEP201706766B (en) 2011-07-22 2012-07-20 Methods and compositions for vaccinating against staphylococcus aureus

Country Status (12)

Country Link
US (1) US10653757B2 (enExample)
EP (1) EP2734229B1 (enExample)
JP (1) JP2014521605A (enExample)
CN (1) CN103998056B (enExample)
AU (1) AU2012287513A1 (enExample)
BR (1) BR112014001409A2 (enExample)
CA (1) CA2842626A1 (enExample)
EA (1) EA035513B1 (enExample)
ES (1) ES2716800T3 (enExample)
GE (1) GEP201706766B (enExample)
UA (1) UA114286C2 (enExample)
WO (1) WO2013015831A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
EP2734229B1 (en) 2011-07-22 2019-01-02 Novadigm Therapeutics, Inc. Methods and copositions for vaccinating against staphylococcus aureus
EP2968501A4 (en) * 2013-03-14 2017-02-15 Rongfu Wang Methods and compositions for modulating regulatory t cell function
WO2014153241A1 (en) * 2013-03-14 2014-09-25 The Regents Of The University Of Michigan Treatment of staphylococcal disorders
CN105407915A (zh) * 2013-03-15 2016-03-16 加州大学洛杉矶分校港口医学中心生物医学研究所 用于治疗真菌性和细菌性病原体的组合物和方法
WO2017155949A1 (en) 2016-03-09 2017-09-14 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis
CN105713096B (zh) * 2016-03-29 2019-01-01 黑龙江八一农垦大学 一种预防金黄色葡萄球菌感染的att融合蛋白的制备及应用
AU2018379996A1 (en) 2017-12-05 2020-06-25 BioPlx, Inc. Methods and compositions to prevent microbial infection
CN112203684A (zh) * 2018-04-10 2021-01-08 海港医学中心洛杉矶生物医学研究所 耳念珠菌感染的治疗方法
CN112940987B (zh) * 2021-04-10 2022-10-14 福建省农业科学院畜牧兽医研究所 一株兔金黄色葡萄球菌及其在制备灭活疫苗中的应用
WO2025032534A2 (en) * 2023-08-09 2025-02-13 Glaxosmithkline Biologicals Sa Modified proteins
WO2025240443A1 (en) * 2024-05-14 2025-11-20 University Of Rochester Candida for use in prevention or mitigation of cutaneous viral infections

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1133829A (en) 1978-08-24 1982-10-19 Neil J.L. Gilmour Pasteurellosis vaccines
US5622939A (en) 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
EP0702516A4 (en) 1993-06-01 1998-04-22 Life Technologies Inc GENETIC IMMUNIZATION WITH CATIONIC LIPIDS
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
AU2657495A (en) 1994-05-23 1995-12-18 Research And Development Institute, Inc. Candida albicans adhesin as a vaccine
US5668263A (en) 1994-12-16 1997-09-16 Smithkline Beecham Corporation Conserved yeast nucleic acid sequences
ES2155129T3 (es) 1995-06-07 2001-05-01 Pfizer Vacunacion in ovo contra la coccidiosis.
AU3126097A (en) 1996-05-16 1997-12-05 The Texas A & M University System Collagen binding protein compositions and methods of use
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6248329B1 (en) 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6703025B1 (en) 1998-08-31 2004-03-09 Inhibitex, Inc. Multicomponent vaccines
US7067138B1 (en) 1999-11-19 2006-06-27 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US8541008B2 (en) 1999-11-19 2013-09-24 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against candidiasis
US20060083750A1 (en) 1999-11-19 2006-04-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis
US20070077256A1 (en) 1999-11-19 2007-04-05 Los Angeles Biomedical Research Institute Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
EP2319301B1 (en) 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human Ig lambda light chain genes
AU2003231818B2 (en) 2002-05-21 2007-04-19 Intervet International B.V. Methods for the in vitro culture of Sporozoea sp. and user thereof
US7241613B1 (en) 2002-06-05 2007-07-10 Oscient Pharmaceuticals Corporation Identification of Candida cell surface proteins and their uses
US7723087B2 (en) 2002-11-12 2010-05-25 The Brigham And Women's Hospital, Inc. Nucleic acid molecules for enhanced production of a bacterial polysaccharide and methods of use thereof
US20070141086A1 (en) * 2003-11-21 2007-06-21 Ohara Michael K Use of antibiotics as vaccine adjuvants
WO2005060713A2 (en) 2003-12-19 2005-07-07 Inhibitex, Inc. Method of inhibiting candida-related infections using donor selected or donor stimulated immunoglobulin compositions
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
WO2006036817A2 (en) 2004-09-24 2006-04-06 Microbia, Inc. Fungal variants and uses thereof
CA2489194A1 (en) 2004-12-03 2006-06-03 Guilhem Janbon Polypeptides involved in candida biofilm formation and uses thereof
WO2007126813A2 (en) 2006-03-29 2007-11-08 Inhibitex, Inc. Cross-reactive monoclonal antibodies recognizing als family proteins
JP5551933B2 (ja) 2006-04-17 2014-07-16 シェーリング−プラウ・リミテッド 組み換え弱毒化Ｃｌｏｓｔｒｉｄｉｕｍ生物体およびワクチン
US20080311135A1 (en) 2007-05-22 2008-12-18 Baylor College Of Medicine Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations
EP2039764A1 (en) * 2007-09-19 2009-03-25 Pevion Biotech AG Truncated secretory aspartyl proteinase 2
WO2009148895A1 (en) 2008-05-29 2009-12-10 Intervet International B.V. Coccidiosis vaccines
US20100150942A1 (en) 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
SI2445522T1 (sl) * 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
NZ597442A (en) 2009-07-03 2014-01-31 Los Angeles Biomed Res Inst Hyr1 as a target for active and passive immunization against candida
WO2012163533A1 (en) 2011-06-01 2012-12-06 Eth Zurich T cell epitope of candida albicans
EP2734229B1 (en) 2011-07-22 2019-01-02 Novadigm Therapeutics, Inc. Methods and copositions for vaccinating against staphylococcus aureus
GB201503812D0 (en) 2015-03-06 2015-04-22 Univ Aberdeen Antibody molecules and uses thereof
WO2017155949A1 (en) 2016-03-09 2017-09-14 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Methods and kits for use in preventing and treating vulvovaginal candidiasis

Also Published As

Publication number Publication date
WO2013015831A1 (en) 2013-01-31
UA114286C2 (uk) 2017-05-25
US20150273031A1 (en) 2015-10-01
BR112014001409A2 (pt) 2017-07-11
EP2734229A4 (en) 2015-01-21
ES2716800T3 (es) 2019-06-17
EP2734229B1 (en) 2019-01-02
AU2012287513A1 (en) 2014-03-13
US10653757B2 (en) 2020-05-19
CN103998056B (zh) 2017-09-12
CA2842626A1 (en) 2013-01-31
EA201391200A1 (ru) 2014-05-30
EP2734229A1 (en) 2014-05-28
EA035513B1 (ru) 2020-06-29
AU2012287513A8 (en) 2014-06-19
CN103998056A (zh) 2014-08-20
JP2014521605A (ja) 2014-08-28

Similar Documents

Publication Publication Date Title
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
PH12015500092A1 (en) Compositions for immunising against staphylococcus aureus
NZ628449A (en) Neisseria meningitidis compositions and methods thereof
MX375202B (es) Composiciones adyuvantes novedosas.
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
DK2280721T3 (da) Indoleamin-2, 3-dioxygenasebaseret immunterapi
AR083561A1 (es) Preparacion de una construccion antigenica
WO2010037395A3 (en) Mhc multimers in cancer vaccines and immune monitoring
BR112012018951C8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
ES2585328T3 (es) Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
AR093712A1 (es) Composicion inmunogena, vacuna, uso y procedimiento de prevencion o tratamiento
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
WO2016176624A3 (en) Porcine pestvirus, vaccines, and assays
EA201391515A1 (ru) Инактивированная вакцина вируса денге
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
CY1113693T1 (el) Φαρμακευτικες συνθεσεις και μεθοδοι για τον εμβολιασμο κατα της διαχυτης καντιντιασης και αλλων μολυσματικων παραγοντων
GB2453491A (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
MX380411B (es) Sistema de marcadores, en particular para antigenos subunitarios expresados por baculovirus.
MX2016001695A (es) Composiciones inmunogenas de combinacion.
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
PH12015502844A1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
MX2016013277A (es) Vacuna para estreptococo de grupo a.
EP4321218A3 (en) Cancer stem cell targeted cancer vaccines
WO2012078051A3 (en) IPN Vaccine